# Acute Hepatic Porphyria

Suspect acute hepatic porphyria in recurrent unexplained neurovisceral attacks, confirm with a creatinine-normalized random urine precursor panel, treat admitted severe attacks with intravenous hemin, and prevent recurrent attacks through trigger control plus givosiran or prophylactic heme therapy.

**Clinical question:** How should physicians confirm, treat, and prevent acute attacks of acute hepatic porphyria?

Updated: 2026-09-16T00:40:17.061872+00:00

## What matters in practice
- Order random urine ALA, PBG, porphyrins, and creatinine when acute hepatic porphyria is clinically plausible; biochemical testing, rather than genetic testing alone, establishes an active diagnosis. [7]
- For an acute attack requiring admission, give intravenous hemin daily, preferably through a high-flow central vein, while treating pain, emesis, autonomic instability, and electrolyte abnormalities. [7]
- Classify recurrent acute attacks as 4 or more attacks per year; consider outpatient givosiran or prophylactic heme therapy in this group. [6][7]
- Obtain genetic confirmation after positive biochemical testing to identify the subtype and enable cascade testing and genetic counseling. [7][9]

## Who warrants acute hepatic porphyria testing?

Test during symptoms whenever possible.

Screen patients with otherwise unexplained recurrent severe abdominal pain after an initial evaluation, particularly women aged 15 to 50 years. Escalate suspicion when attacks include nausea, confusion, hyponatremia, tachycardia, hypertension, or motor-predominant neuropathy; these features occur across acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP). [7][4][14]

Do not use nonspecific abdominal pain, psychiatric symptoms, or a family history alone to diagnose AHP. Acute attacks can mimic common gastrointestinal, neurologic, and psychiatric conditions, and the diagnostic pathway begins with biochemical evidence of excess heme-pathway intermediates. [4][6][7]

Cutaneous photosensitivity or blistering shifts the subtype differential toward VP or HCP: skin lesions accompany attacks in approximately one-half of VP and one-third of HCP cases, whereas AIP is principally neurovisceral. This distinction should prompt specialty porphyrin characterization after biochemical confirmation rather than delay initial urine precursor testing. [14][11]
- Treat rapidly progressive proximal weakness, quadriparesis, or respiratory compromise as an admission-level neurologic emergency; AHP neuropathy can progress to respiratory paralysis. [14]
- Review new medications, alcohol exposure, hormonal therapies, fasting or reduced caloric intake, dehydration, infection, and other intercurrent illness because multiple triggers may be additive. [7][10][11]

*Clinical patterns that should change the urgency and direction of AHP evaluation. [4][7][14]*

| Pattern | Interpretation | Next action |
| --- | --- | --- |
| Recurrent severe abdominal pain with no established cause | AHP screening indication, especially in women aged 15-50 years. [7] | Order random urine ALA, PBG, porphyrins, and creatinine. [7] |
| Pain plus hyponatremia, tachycardia, hypertension, confusion, or neuropathy | Supports an acute neurovisceral attack and raises need for inpatient monitoring. [4][7] | Obtain urine precursors promptly and manage physiologic complications while evaluating alternative emergencies. [7] |
| Neurovisceral symptoms plus blistering photosensitivity | Suggests VP or HCP rather than isolated AIP. [14] | After biochemical confirmation, obtain specialist plasma and fecal porphyrin studies for subtype assignment. [11] |
| Progressive motor weakness or respiratory involvement | Potentially life-threatening porphyric neuropathy. [14] | Admit and monitor respiratory status; initiate attack-directed treatment when AHP is established. [7][14] |

## How to confirm an acute hepatic porphyria attack

Use a single random urine specimen rather than waiting for a 24-hour collection.

For initial evaluation, measure urinary porphobilinogen (PBG), δ-aminolevulinic acid (ALA), total porphyrins, and creatinine in a random urine specimen. Creatinine permits interpretation despite variable urine concentration, and this panel is the AGA-recommended initial diagnostic test set for AHP. [7][4]

A positive biochemical screen should be followed by molecular genetic testing to confirm AHP and identify the pathogenic variant. Genetic testing is most useful after biochemical evidence of disease activity and then supports counseling and cascade testing of relatives. [7][9][12]

When a newly confirmed patient has no prior family diagnosis, use light-protected plasma and fecal porphyrin analysis in a specialist laboratory to distinguish AIP, VP, and HCP. Plasma fluorescence emission and fecal porphyrin-excretion patterns provide subtype discrimination; urinary precursor elevation alone establishes AHP activity but may not define the specific subtype. [11]

A urine dipstick urobilinogen result is not a replacement for PBG and ALA measurement. In one abdominal-pain study, a urinary urobilinogen-to-serum total bilirubin ratio above 3.22 identified AIP, HCP, and VP with reported 100% sensitivity and specificity; use it only as a prompt for definitive urinary PBG, ALA, and, when indicated, genetic testing. [2]
- If the patient has a documented prior biochemical diagnosis, a clinically typical acute neurovisceral presentation can establish a recurrent attack without waiting to identify the exact AHP subtype. [15]
- A latent inactive AIP state is defined by no prior AHP manifestations and a urine PBG-to-creatinine ratio less than four times the upper limit of normal; this is not evidence of an acute attack. [12]

*Sequential diagnostic testing for suspected AHP. [7][11][12]*

| Test | Use | Result-driven next step |
| --- | --- | --- |
| Random urine PBG, ALA, porphyrins, and creatinine | Initial biochemical evaluation during suspected attack. [7] | If biochemical testing is positive, proceed to molecular confirmation and subtype workup. [7] |
| Molecular genetic testing | Confirms the diagnosis after positive biochemical testing and identifies the familial variant. [7][9] | Offer cascade testing and genetic counseling to at-risk relatives. [9][11] |
| Light-protected plasma and fecal porphyrin analysis | Specialist subtype discrimination in a newly confirmed patient. [11] | Use fluorescence and fecal excretion patterns to differentiate AIP, VP, and HCP. [11] |
| Urine PBG-to-creatinine ratio | Distinguishes inactive latent AIP from active biochemical expression. [12] | A ratio less than 4 times ULN with no manifestations defines latent inactive AIP. [12] |

## How to manage an acute neurovisceral attack

Stabilize complications while suppressing hepatic precursor production.

Hospitalize patients with severe attacks, inability to maintain oral intake, significant autonomic instability, hyponatremia, progressive neuropathy, or concern for respiratory weakness. For attacks severe enough to require admission, administer intravenous hemin daily, preferably through a high-flow central vein. Treatment does not require determination of the exact AHP subtype once an acute porphyria diagnosis is biochemically established. [7][15]

Manage the attack in parallel: provide analgesia, antiemetics, and directed treatment of systemic hypertension, tachycardia, hyponatremia, and hypomagnesemia. Use only medications considered safe for porphyria and discontinue identifiable porphyrinogenic drugs. [7][14]

For mild acute neurovisceral attacks, use high carbohydrate intake, preferably orally. If intravenous carbohydrate is required for up to 48 hours, GeneReviews describes glucose-containing fluid with at least 5% dextrose; 10% glucose with sodium 40 mmol and potassium 20 mmol in 1,000 mL over 12 hours is commonly recommended. Avoid hypotonic dextrose-in-water solutions because they can worsen hyponatremia. [12]

Hemin infusion technique affects vascular risk. Reconstituting hematin in 20% human serum albumin and using a large peripheral vein or central catheter can reduce phlebitis; use an in-line filter, replace a peripheral cannula after each administration, and flush venous catheters with a total 200 mL saline bolus. [12]
- Assess and treat intercurrent infection or other acute illness promptly because these can precipitate or perpetuate attacks. [10][12]
- For severe pain, opioids including morphine have been described as non-porphyrogenic; propranolol may relieve sympathetic tachycardia and hypertension. [14]
- Before anesthesia or procedures, prevent prolonged fasting and dehydration and avoid porphyrinogenic medications; anesthesia can be administered safely with these precautions. [5][11]

### When to consider transplant

Refer for liver transplantation evaluation only when symptoms are intractable, quality of life is markedly impaired, and pharmacotherapy has failed. This is a rescue strategy rather than routine treatment for recurrent attacks. [7]

*Acute attack management by clinical severity. [7][12][14][15]*

| Clinical setting | Immediate treatment | Monitoring or escalation |
| --- | --- | --- |
| Mild attack with oral intake preserved | High carbohydrate intake, preferably oral; identify and remove triggers. [12] | Reassess for evolving neuropathy, dysnatremia, autonomic instability, or inability to maintain intake. [7][12] |
| Attack requiring admission | IV hemin daily, preferably through a high-flow central vein; add analgesia and antiemetics. [7] | Monitor and correct hypertension, tachycardia, hyponatremia, and hypomagnesemia. [7] |
| Progressive motor weakness or respiratory concern | Hospital-level acute attack treatment with IV hemin when AHP is established. [7][15] | Escalate respiratory monitoring because neuropathy can progress to respiratory paralysis. [14] |
| IV carbohydrate needed temporarily | Use glucose-containing IV fluid for up to 48 hours; avoid hypotonic dextrose in water. [12] | Monitor sodium and potassium; hypotonic solutions increase hyponatremia risk. [12] |

## How to prevent recurrent attacks

Escalate from trigger control to disease-modifying prophylaxis based on attack frequency.

Define recurrent acute attacks as 4 or more attacks annually; distinguish these patients from those with sporadic attacks occurring fewer than 4 times per year. Recurrent disease warrants close follow-up because attack prevention, treatment modification, and complication surveillance are more likely to be necessary. [6]

At every recurrence, perform a medication review that includes hormonal contraception, assess alcohol exposure, investigate infection or other intercurrent disease, and obtain dietary and nutritional history. Avoid identifiable precipitants, including alcohol and porphyrinogenic medications; reduced caloric intake, prolonged fasting, dehydration, and certain hormonal exposures are actionable trigger domains. [7][10][11]

For recurrent acute attacks, consider outpatient prophylactic heme therapy or givosiran. Givosiran is an siRNA therapy directed against hepatic ALAS1 and has demonstrated reduction in acute attacks in a phase III trial; selection between prophylactic heme and givosiran should occur with porphyria expertise because ongoing attack burden and treatment response drive modification. [7][4][23]

Refer every patient who has experienced an acute attack to a porphyria specialist for longitudinal care. Annual assessment should include biochemical testing and monitoring for long-term complications, with follow-up frequency intensified for recurrent attacks and patients receiving treatment changes. [6][11]
- Offer genetic counseling and targeted cascade testing after a pathogenic variant is identified. [7][9][11]
- Use a current porphyria-safe medication resource before prescribing, especially when starting anticonvulsants, hormonal agents, perioperative drugs, or psychotropics. [10][11]
- Do not pursue liver transplantation before pharmacotherapy has failed and symptoms remain intractable with substantially impaired quality of life. [7]

*Long-term AHP management according to clinical subgroup. [6][7][11]*

| Clinical subgroup | Operational definition | Management priority |
| --- | --- | --- |
| Sporadic attacks | Fewer than 4 attacks per year. [6] | Identify triggers, treat attacks promptly, and monitor for change in frequency or complications. [6][7] |
| Recurrent acute attacks | 4 or more attacks per year. [6][7] | Consider outpatient givosiran or prophylactic heme therapy with close follow-up. [7] |
| Asymptomatic high precursor excretor | No symptoms but elevated porphyrin precursors. [6] | Annual biochemical and complication monitoring; counsel regarding triggers. [6] |
| Latent inactive AIP | No manifestations and urine PBG-to-creatinine ratio less than 4 times ULN. [12] | Genetic counseling and trigger avoidance; do not label an acute attack without compatible biochemical and clinical evidence. [7][12] |

## How to manage procedures and family risk

Prevent iatrogenic attacks and identify relatives before an emergency presentation.

A known AHP diagnosis is not a contraindication to anesthesia. Before elective procedures, avoid porphyrinogenic medicines, prolonged fasting, dehydration, and inadequate analgesia; coordinate the medication plan with an anesthesia team and a current porphyria drug-safety resource. [5][11]

After positive biochemical testing, genetic confirmation should be used to identify the pathogenic variant and facilitate cascade testing. Family testing is clinically useful because many carriers remain asymptomatic, while identification permits anticipatory counseling regarding medications, alcohol, fasting, and other triggers. [7][9][11]
- Light-protect plasma and fecal specimens when specialist porphyrin studies are being used for subtype determination. [11]
- Document the established biochemical diagnosis and safe-medication precautions prominently in the medical record before emergency care or procedures. [7][11]

*Care transitions that require an AHP-specific plan. [5][7][9][11]*

| Transition | Required action | Reason |
| --- | --- | --- |
| Elective surgery or anesthesia | Avoid porphyrinogenic drugs, prolonged fasting, dehydration, and inadequate analgesia. [5][11] | These exposures can precipitate acute neurovisceral attacks. [5][11] |
| New biochemical diagnosis | Confirm genetically and refer to a porphyria specialist. [7][11] | Subtype definition, family evaluation, and longitudinal management follow confirmation. [7][11] |
| At-risk relatives | Offer cascade testing after identification of the familial pathogenic variant. [9][11] | Identifies relatives who need trigger counseling before symptomatic disease occurs. [9][11] |

## References
1. [PDF] Administrative and Correspondence Documents - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212194Orig1s000AdminCorres.pdf
2. A high urinary urobilinogen/serum total bilirubin ratio indicates acute hepatic porphyria in patients with abdominal pain | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-023-48824-9
3. The diagnostic potential of urine in paediatric patients undergoing initial treatment for tuberculous meningitis | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-024-70419-1
4. Acute hepatic porphyrias: Recommendations for diagnosis and management with real-world examples — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1096719223003001
5. Acute hepatic porphyria and anaesthesia: a practical approach to ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2058534920301414
6. Acute hepatic porphyrias: Recommendations for evaluation and long-term management - PubMed — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/28605040
7. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10335308
8. [PDF] Highly Specialised Technology Evaluation Givosiran for treating ... — www.nice.org.uk — https://www.nice.org.uk/guidance/hst16/documents/committee-papers-2
9. Acute hepatic porphyrias: Recommendations for diagnosis and management with real-world examples. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/37542766
10. Acute Hepatic Porphyrias: Current Diagnosis & Management — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6911835
11. Acute hepatic porphyria and anaesthesia: a practical approach to the prevention and management of acute neurovisceral attacks — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7810766
12. Acute Intermittent Porphyria - GeneReviews® - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK1193
13. Acute Intermittent Porphyria - GeneReviews® - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/sites/books/NBK1193
14. Diagnosis and management of porphyria - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC1127427
15. Acute Hepatic Porphyria - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK537178
16. Acute Intermittent Porphyria - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK547665
17. Clinical Guide and Update on Porphyrias - Gastroenterology — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(19)40883-4/fulltext
18. Clinical Guide and Update on Porphyrias — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(19)40883-4/pdf
19. MRI Brain Imaging Patterns in Acute Intermittent Porphyria - AJNR — www.ajnr.org — https://www.ajnr.org/content/early/2026/07/11/ajnr.A9524.full.pdf
20. Neonatal-onset hereditary coproporphyria with male ... — ashpublications.org — https://ashpublications.org/blood/article/98/13/3871/90259/Neonatal-onset-hereditary-coproporphyria-with-male
21. Intermittent Unexplained Abdominal Pain: Is It Porphyria? — www.gastrojournal.org — https://www.gastrojournal.org/article/S1542-3565(07)00898-1/fulltext
22. Neurovisceral Porphyrias: What a Hematologist Needs to Know — ashpublications.org — https://ashpublications.org/hematology/article/2005/1/24/19286/Neurovisceral-Porphyrias-What-a-Hematologist-Needs
23. Hereditary Coproporphyria - PubMed — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/23236641
24. Iron physiology, iron overload, and the porphyrias - ASH Publications — ashpublications.org — https://ashpublications.org/books/book/8/chapter/10647185/Iron-physiology-iron-overload-and-the-porphyrias

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.